Dashboard
Manage Tickers

PPBT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

purple-biotech-says-eu-patent-office-issues-intention-to-grant-european-patent-for-combinations-of-irsstat3-dual-modulators-and-anti-cancer-agents-for-treating-cancer
Purple Biotech Says EU Patent Office Issue...
09/10/2025 12:07:54

A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
09/05/2025 17:06:13

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 17:05:59

purple-biotech-prices-6m-public-offering-of-6m-adss-or-pre-funded-warrants-at-a-combined-price-of-100-short-term-warrants-to-purchase-up-to-12m-adss-at-100-for-up-to-12m-in-potential-additional-proceeds
Purple Biotech Prices $6M Public Offering ...
09/04/2025 13:19:00

$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of shor...

purple-biotech-unveils-cancer-data-on-new-tri-specific-antibody-im1240
Purple Biotech Unveils Cancer Data On New ...
09/04/2025 11:18:32

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developin...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/03/2025 12:08:15

purple-biotech-announced-its-second-captn-3-trispecific-antibody-im1305-targeting-trop2-in-development-fda-investigational-new-drug-submission-planned-for-2026
Purple Biotech Announced Its Second CAPTN-...
09/03/2025 11:14:15

IM1305 (capped-CD3xTROP2xNKG2A) contains a masked anti-CD3 arm, as well as an anti-NKG2A arm, and an anti-TROP2 arm. The potent...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/02/2025 17:06:49

purple-biotech-q2-eps-040-beats-062-estimate
Purple Biotech Q2 EPS $(0.40) Beats $(0.62...
08/06/2025 11:17:47

purple-biotechs-chief-executive-officer-gil-efron-issued-a-letter-to-shareholders-highlighting-the-companys-scientific-progress-operational-execution-and-strategic-milestones-during-1h-2025
Purple Biotech's Chief Executive Officer G...
07/24/2025 11:29:42

2025 First Half HighlightsCM24 (α-CEACAM1 monoclonal antibody)Our Phase 2 dataset demonstrated strong objective response rates ...

purple-biotech-presents-new-preclinical-data-on-captn-3-tri-specific-antibody-platform-at-eacr-2025
Purple Biotech Presents New Preclinical Da...
06/23/2025 11:06:10

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developin...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

purple-biotech-initiated-phase-2-study-evaluating-nt219-in-patients-with-recurrent-andor-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
Purple Biotech Initiated Phase 2 Study Eva...
06/17/2025 11:05:00

NT219 is a novel small molecule designed to target two key oncogenic pathways: IRS1/2 (Insulin Receptor Substrates 1 and 2) and...

purple-biotech-q1-eps-017-misses-006-estimate
Purple Biotech Q1 EPS $(0.17) Misses $(0.0...
05/21/2025 11:14:36

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0....

purple-biotechs-cm24-shows-up-to-90-reduction-in-death-risk-in-pancreatic-cancer-patients-biomarker-insights-to-drive-next-phase-2b-study
Purple Biotech's CM24 Shows Up To 90% Redu...
04/30/2025 11:08:30

Statistically significant efficacy in biomarker subgroup analyses was observed: 78% reduction in risk of death and 81% reductio...

purple-biotech-reports-data-at-aacr-for-colorectal-and-head-and-neck-cancer
Purple Biotech Reports Data At AACR For Co...
04/28/2025 12:29:45

Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in th...

purple-biotech-announced-today-the-publication-of-an-independent-study-titled-irs2-as-a-driver-of-brain-metastasis-in-colorectal-cancer-a-potential-target-for-novel-therapeutic-strategies-in-the-peer-reviewed-journal
Purple Biotech Announced Today The Publica...
04/16/2025 11:03:32

purple-biotech-to-present-cm24-and-nt219-data-for-pancreatic-colorectal-and-head-and-neck-cancers-at-2025-aacr-meeting
Purple Biotech To Present CM24 And NT219 D...
03/28/2025 11:48:33

purple-biotech-q4-epads-026
Purple Biotech Q4 EPADS $(0.26)
03/10/2025 12:58:53

purple-biotech-granted-us-patent-for-nt219-in-combination-with-egfr-antibody-therapy-for-treating-cancer-patients-who-have-acquired-resistance-to-egfr-therapies
Purple Biotech Granted US Patent For NT219...
03/05/2025 12:11:26

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION